GMl治疗61例急性脑卒中的疗效观察

目的:评价GMI治疗急性脑卒中(脑出血和脑梗塞)的疗效。方法:130例急性脑卒中病例随机分成两组。应用GMl组(61例)为治疗组,未用GMl组(69例)为对照组。治疗组除应用GMl外,两组治疗基本相同。观察两组治疗前、治疗2周后、治疗4周后的NDS(脑卒中患者临床神经功能缺损程度评分量表)和ADL(日常生活量表),并进行评分比较。结果:治疗前两组NDS和ADL评分比较无统计学差异,治疗2周、4周后有明显统计学差异。治疗组中治疗前与治疗2周、4周后比较有显著性差异,而治疗2周与4周后比较无统计学差异。结论:急性脑卒中病人应用GMI可明显改善临床症状,降低致残率,提高患者的生活自理能力。

Objective： To evaluate the therapeutic effects of GM1 on acute cerebral stroke. Methods： 130 cases with acute cerebral stroke were divided into two groups randomly, the patients received GM1 （61 cases） are therapeutic group, the others are control group. Except for routine treatment, the former received NS 100 ml＋GM1 40mg ivgtt qd×12 days. The latter received routine treatment. We observed and compared NDS/ADL in different time. Results： The two groups had no statistics difference in NDS and ADL before treatment, but they had obvious statistics difference after two and four weeks. There is obvious statistics difference between before and after treatment in therapeutic group, but there is no difference between two and four weeks after treatment. Conclusion： GM1 can greatly improve clinical symptoms, reduce the rate of handicao, and imorove the ability of life.